Picoregulon® (Tablets, Drops) Instructions for Use
ATC Code
A06AB08 (Sodium picosulfate)
Active Substance
Sodium picosulfate (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Laxative drug
Pharmacotherapeutic Group
Drugs for the treatment of constipation; contact laxatives
Pharmacological Action
Laxative. Under the action of intestinal microorganisms, it is hydrolyzed to form an active form, which irritates the receptors of the intestinal mucosa and enhances its peristalsis.
It promotes the accumulation of water and electrolytes in the large intestine, which leads to stimulation of defecation, reduction of evacuation time, and softening of stool.
Pharmacokinetics
After oral administration, it is not absorbed from the gastrointestinal tract and does not undergo enterohepatic circulation.
In the distal part of the large intestine, sodium picosulfate is cleaved to form the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane. The time to onset of the laxative effect is determined by the rate of release of the active metabolite and is 6-12 hours.
Approximately 10.4% of the total dose is excreted by the kidneys as a glucuronide within 48 hours.
Indications
Constipation due to atony and hypotension of the colon (including in the elderly, in bedridden patients, after surgery, after childbirth and during lactation); constipation caused by medication; constipation due to intestinal dysbiosis, dietary disorders; for regulating stool in hemorrhoids, proctitis, anal fissures; gallbladder diseases, irritable bowel syndrome with predominant constipation.
ICD codes
| ICD-10 code | Indication |
| K59.0 | Constipation |
| K60 | Fissure and fistula of anus and rectum |
| K62.8 | Other specified diseases of anus and rectum (including proctitis) |
| K64 | Hemorrhoids and perianal venous thrombosis |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| DB32.1 | Slow-transit constipation |
| DB50.Z | Fissure or fistula of anal region, unspecified |
| DB6Z | Hemorrhoids or perianal venous diseases, unspecified |
| DB70.Z | Infections of anal and rectal regions, unspecified |
| DB72.Z | Some specified diseases of the anal canal, unspecified |
| DD91.1 | Functional constipation |
| DE2Z | Diseases of the digestive system, unspecified |
| EG61 | Infections of the anus or perianal skin |
| QB9A | Preparatory procedures for subsequent treatment |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer orally. Determine the dose individually based on patient age and clinical response.
For adults and children over 10 years, the usual dose is 10-20 mg (5-10 ml of drops or 2-4 tablets) taken once daily.
For children aged 4 to 10 years, the usual dose is 5-10 mg (2.5-5 ml of drops or 1-2 tablets) taken once daily.
For children aged 1 to 4 years, use only the drop formulation; the usual dose is 0.15 ml/kg body weight (approximately 5-8 drops), not to exceed 5 mg (2.5 ml) per day.
For bowel preparation before diagnostic procedures, follow a split-dose regimen as directed by a physician.
Take the dose in the evening before bedtime. The laxative effect typically occurs after 6-12 hours.
For ease of administration to children, the tasteless drops can be mixed with water, juice, or food.
Do not use for more than 10 consecutive days without medical supervision.
If constipation persists despite treatment, discontinue use and consult a physician to investigate the underlying cause.
Adverse Reactions
From the digestive system dyspepsia, flatulence, nausea, vomiting, abdominal cramps and pain, diarrhea.
From the nervous system dizziness, fainting, drowsiness, increased fatigue.
From the immune system allergic reactions, angioedema, allergic dermatitis.
From the skin and subcutaneous tissues skin rash, urticaria, itching.
From metabolism increased excretion of potassium, sodium and other electrolytes, dehydration.
Contraindications
Hypersensitivity to sodium picosulfate; intestinal obstruction or obstructive bowel diseases; acute diseases of the abdominal organs or severe abdominal pain that may be accompanied by nausea, vomiting, fever, including appendicitis; acute inflammatory bowel diseases; severe dehydration; first trimester of pregnancy; pediatric age – depending on the dosage form.
With caution elderly age, hypokalemia, increased blood magnesium concentration, asthenia, renal failure.
Use in Pregnancy and Lactation
Contraindicated for use in the first trimester of pregnancy. Use in the second and third trimesters of pregnancy should only be if the intended benefit to the mother outweighs the potential risk to the fetus.
The active metabolite and its glucuronides are not excreted in breast milk. It can be used during lactation (breastfeeding) according to indications in recommended doses.
Use in Renal Impairment
Should be used with caution in patients with impaired renal function.
Pediatric Use
Can be used in children according to indications, in age-appropriate recommended doses and dosage forms. It is necessary to strictly follow the instructions in the sodium picosulfate drug labels regarding contraindications for the use of specific sodium picosulfate dosage forms in children of different ages.
Geriatric Use
Should be used with caution in elderly patients.
Special Precautions
The product is tasteless, so it can be added to food for children. Do not use daily without medical supervision for more than 10 days.
Dizziness and fainting occurring after taking sodium picosulfate may be associated with a vasovagal reaction (e.g., straining during defecation, abdominal cramps).
The possibility of spontaneous defecation cannot be excluded. If the nature of the stool does not change for a long time while taking sodium picosulfate, it is necessary to consult a doctor to determine the cause of constipation.
Studies on the effect of sodium picosulfate on fertility have not been conducted. No teratogenic effects were identified.
Effect on ability to drive vehicles and operate machinery
If vasovagal reactions occur in patients while taking the product, they should avoid driving vehicles and engaging in other activities requiring high concentration and speed of psychomotor reactions.
Drug Interactions
With simultaneous use with broad-spectrum antibiotics, a decrease in the laxative effect of sodium picosulfate is possible.
With simultaneous use with diuretics, with corticosteroids, an increased risk of electrolyte disturbances is possible.
Electrolyte imbalance occurring while taking sodium picosulfate in high doses may lead to worsened tolerance of cardiac glycosides with their simultaneous use.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Tablets 5 mg: 20, 30, or 50 pcs.
Marketing Authorization Holder
Vertex, JSC (Russia)
Dosage Form
| Picoregulon® | Tablets 5 mg: 20, 30, or 50 pcs. |
Dosage Form, Packaging, and Composition
Tablets white or almost white, oblong, biconvex, with a score on one side.
| 1 tab. | |
| Sodium picosulfate (in the form of sodium picosulfate monohydrate) | 5 mg |
10 pcs. – blister packs (2 pcs.) – cardboard packs (20 pcs.) – Over-the-Counter
10 pcs. – blister packs (3 pcs.) – cardboard packs (30 pcs.) – Over-the-Counter
10 pcs. – blister packs (5 pcs.) – cardboard packs (50 pcs.) – Over-the-Counter
15 pcs. – blister packs (2 pcs.) – cardboard packs (30 pcs.) – Over-the-Counter
50 pcs. – jars – cardboard packs (50 pcs.) – Over-the-Counter
Oral drops 7.5 mg/1 ml: 15 ml or 30 ml bottle
Marketing Authorization Holder
Vertex, JSC (Russia)
Dosage Form
| Picoregulon® | Oral drops 7.5 mg/1 ml: 15 ml or 30 ml bottle |
Dosage Form, Packaging, and Composition
Oral drops
| Sodium picosulfate | 7.5 mg/ml |
15 ml – bottles – cardboard packs – Over-the-Counter
30 ml – bottles – cardboard packs – Over-the-Counter
